In a matter of weeks the fate of a popular cancer drug will be decided by the Food and Drug administration. It will be talked about whether it should continue to be approved for treating breast cancer.

Kaye Stevens was left with scars while battling out her breast cancer and she has loads of medication to show that was given to her but the one drug that she swears by is Avastin, made by the Bay Area giant Genentech, and said that it extended her life.

She said, "I've been able to function have a relatively decent quality of life without tremendous side effects, and I've been tumor free."

Avastin as a stand-alone treatment nearly two years ago was given by Berkeley oncologist Dr. Gary Cecche to Kaye after she showed severe side effects from other drug combinations.

The doctor said, "So for her it's not only improved her response, one would have to believe it's dramatically improved her survival."

Avastin’s statistical effectiveness in treating breast cancer in a majority of women was questioned by recent studies reviewed by an FDA panel in July.

It was stated by certain tests combining Avastin with several other drugs that the progression of tumors by about a month to two and a half months on average was delayed.